Radioligands for Central Neuroreceptors
- 126 Downloads
In the development of a new radioligand for a (sub)type of a central neuroreceptor, the selection of the ligand is of crucial importance. It should possess high affinity and selectivity for the concerned receptor type and be able to enter the brain without giving high nonspecific binding. Metabolism of the ligand is preferably slow or results in labelled metabolites that are unable to enter the brain. The incorporated radioisotope should have a physical half-life compatible with the imaging study done and its radiation should be of the correct type and energy to be detected by the external imaging system. Before entering the final developmental stage of in vivo evaluation in animals and human volunteers, a number of (radio)pharmaceutical quality control criteria should be drawn up for the new potential radioligand.
KeywordsHigh Performance Liquid Chromatography Single Photon Emission Compute Tomography European Pharmacopoeia Radionuclidic Purity Positron Emission Tomography Camera
Unable to display preview. Download preview PDF.
- Dichino DD, Welch MJ, Kilbourn MR, Raichle ME (1983) Relationship between lipophilicity and brain extraction of C-11 labeled radiopharmaceuticals. J Nucl Med 24:1030–1038Google Scholar
- European Pharmacopoeia (1997) Radiopharmaceutical preparations 1997:0125, pp 1424–1433Google Scholar
- Meyer GJ, Coenen HH, Waters SL, Langström B, Cantineau R, Strijckmans K, Vaalburg W, Halldin C, Crouzel C, Mazière B, Luxen A (1993) Quality assurance and quality control of short-lived radiopharmaceuticals for PET. In: Stöcklin G, Pike VW (eds) Radiopharmaceuticals for positron tomography — methodological aspects. Kluwer Academic, Dordrecht, pp 91–147CrossRefGoogle Scholar
- Pardridge WM (1991) Peptide drug delivery to the brain. Raven, New YorkGoogle Scholar
- Waterhouse RN, Mardon K, Giles KM, Collier TL, O’Brien JC (1997) Halogenated 4-(phenoxy methyl)piperidines as potential radiolabelled probes for sigma-1 receptors: in vivo evaluation of [123I]-l-(iodopropen-2-yl)-4-[(4-cyanophenoxy)methyl]piperidine. J Med Chem 40: 1657–1667PubMedCrossRefGoogle Scholar